PHVS

31.4200.76%
RG

Robert Glassman

Independent Non-Executive Director

Dr. Robert Glassman, also known as Rob, M.D., Ph.D., served as an Independent Director of Portage Biotech Inc. since July 1, 2022 until April 25, 2024. He serves as the Executive Vice President of Search & Evaluation for Enavate Sciences from July 2022. Dr. Glassman also serves as a board member for EluraBio and he is an advisor at Centrexion. He has healthcare banking, venture investing and advisory experience. He is VP of Search and Evaluation at Enavate Sciences. He is former Independent Director of Tarus Therapeutics. He was Venture Partner of Public Equity at OrbiMed Advisors LLC. Dr. Glassman was Private Equity Partner of OrbiMed Advisors LLC from 2009 to 2010. He works in the public equity team. He has been Independent Non-Executive Director of Pharvaris B.V. since January 2021. He was Independent Non-Executive Director of Umoja BioPharma, Inc. since January 1, 2021 until September 2025. Dr. Glassman serves as Managing Director at Global Healthcare Corporate. Dr. Glassman serves as a Venture Advisor at Israel Biotech Fund. He served as a Member of Business Advisory Board at Zentalis Pharmaceuticals, Inc. until 2022. Previously Dr. Glassman was a Senior Investment Banker at healthcare investment banking at Merrill Lynch and a Consultant at McKinsey & Co. Dr. Glassman served as the President at Merrill Lynch Ventures. Before he worked with Merrill Lynch, Dr. Glassman was with McKinsey & Company, Inc. consulting for health care clients in the U.S. and Europe. Previously, Dr. Glassman had been working as a senior investment banker. He has been Vice Chairman at Credit Suisse Securities since 2015. Earlier in his career, Dr. Glassman was with Merrill Lynch Global Private Equity, where he oversaw a successful healthcare portfolio and McKinsey & Co, where he consulted for a wide range of clients within their Pharmaceutical and Medical Products practice. Prior to joining Credit Suisse Securities, Dr. Glassman served as a Managing Director at Bank of America Merrill Lynch between 2010-2015. Dr. Glassman served as Director of Epigenesis Pharmaceuticals; Inc. Dr. Glassman is a board-certified hematologist-oncologist who remains on the faculty as a Clinical Assistant Professor of Medicine at Weill Cornell. He has co-authored numerous articles in peer-reviewed journals and spoken widely in industry and academic forums on clinical development, reimbursement and data interpretation. He completed his residency in internal medicine at the Hospital of the University of Pennsylvania and his fellowship in hematology and oncology at Weill Cornell. He has also held academic positions at Cornell University. He also worked as a basic science investigator at Rockefeller University in the laboratory of Hidesaburo Hanafusa, where he received Howard Hughes Medical Institute and American Cancer Society awards. Dr. Glassman has M.D. in Medicine from Harvard Medical School from 1979 to 1987, A.B., magna cum laude, in Biological Sciences and Biology, General from Harvard College from 1979 to 1983.

Positions